Scholar Rock (NASDAQ:SRRK) Announces Quarterly Earnings Results

Key Points

• Scholar Rock reported a quarterly loss of $0.81 per share, beating the consensus estimate of a $0.85 loss; revenue was $0.57 million versus a $0.30 million estimate.
• ISEMBYLD’s U.S. launch saw early demand across patient groups and treatment centers, but access hurdles may delay many initial infusions until 2027.
• The company ended the quarter with $413.6 million in cash and marketable securities and raised $205 million from a priority review voucher sale; it also reported progress in apitegromab regulatory reviews in Europe and Japan.

Scholar Rock (NASDAQ:SRRK - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.04, FiscalAI reports. The company had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.30 million. During the same period last year, the company earned ($0.90) EPS.

Here are the key takeaways from Scholar Rock's conference call:

• ISEMBYLD’s U.S. launch showed broad early demand: enrollments came from across the country, included treatment-naive patients as well as children and adults, and reached more than one-third of the top 140 SMA treatment centers within six weeks.
• Access delays are likely to push many initial infusions into 2027. The company said prescription-to-infusion timelines can exceed 60–90 days as patients navigate prior authorization, payer policies, and hospital formularies; an ISEMBYLD-specific J-code is expected April 1, 2027.
• Global regulatory progress advanced: apitegromab’s European application was resubmitted and validated, with a CHMP opinion expected in the first half of 2027, while Japan accepted its application for priority review, supporting a potential launch near year-end 2027.
• The company strengthened its financial position with a $205 million agreement to sell its priority review voucher. Scholar Rock reported $413.6 million in cash, equivalents, and marketable securities at quarter-end and said it does not need an equity offering at this time.
• Pipeline programs continued to progress: dosing began in the phase II FORGE study of apitegromab in FSHD, enrollment is ongoing in the under-two OPAL study, and SRK-439 phase I dosing is progressing, with top-line data expected by year-end and an update planned for early 2027.

Scholar Rock Trading Down 5.7%

Shares of NASDAQ SRRK traded down $2.94 during midday trading on Tuesday, hitting $48.62. The company's stock had a trading volume of 372,536 shares, compared to its average volume of 1,456,550. The company has a current ratio of 7.02, a quick ratio of 7.02 and a debt-to-equity ratio of 0.77. The business's 50 day moving average is $47.01 and its two-hundred day moving average is $48.22. Scholar Rock has a 12-month low of $28.97 and a 12-month high of $61.76. The firm has a market cap of $5.92 billion, a P/E ratio of -14.11 and a beta of 0.78.

Insider Transactions at Scholar Rock

In other Scholar Rock news, Director Srinivas Akkaraju acquired 146,970 shares of the business's stock in a transaction on Monday, October 26th. The shares were bought at an average price of $41.59 per share, with a total value of $6,112,482.30. Following the transaction, the director directly owned 6,380,517 shares of the company's stock, valued at $265,365,702.03. The trade was a 2.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 10.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

SRRK has been the subject of a number of research reports. Piper Sandler increased their target price on Scholar Rock from $60.00 to $75.00 and gave the company an "overweight" rating in a research report on Tuesday, September 15th. Truist Financial boosted their price target on shares of Scholar Rock from $76.00 to $77.00 and gave the stock a "buy" rating in a research report on Thursday, September 24th. BMO Capital Markets upped their price target on shares of Scholar Rock from $76.00 to $84.00 and gave the company an "outperform" rating in a research note on Monday, September 14th. Wedbush reiterated an "outperform" rating and set a $64.00 price objective on shares of Scholar Rock in a research report on Tuesday, September 15th. Finally, UBS Group reissued a "buy" rating on shares of Scholar Rock in a research note on Tuesday, September 15th. Four research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $67.67.

About Scholar Rock

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation.

The company's lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients' motor function.

Scholar Rock was founded in 2012.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.